QuidelOrtho (NASDAQ:QDEL) Posts Quarterly Earnings Results, Misses Expectations By $0.44 EPS

QuidelOrtho (NASDAQ:QDEL) issued its quarterly earnings results on Wednesday. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.07 by ($0.44), Zacks reports. QuidelOrtho had a negative net margin of 66.25% and a positive return on equity of 4.24%. QuidelOrtho updated its FY 2025 guidance to 2.070-2.570 EPS.

QuidelOrtho Price Performance

Shares of NASDAQ:QDEL traded down $1.53 during trading on Wednesday, hitting $39.94. 1,309,639 shares of the company were exchanged, compared to its average volume of 889,851. The business’s 50 day moving average is $43.28 and its 200-day moving average is $42.36. The company has a market capitalization of $2.69 billion, a P/E ratio of -1.43 and a beta of 0.08. The company has a quick ratio of 0.81, a current ratio of 1.38 and a debt-to-equity ratio of 0.68. QuidelOrtho has a 1-year low of $29.74 and a 1-year high of $68.85.

Analysts Set New Price Targets

QDEL has been the subject of several recent research reports. William Blair reiterated a “market perform” rating on shares of QuidelOrtho in a research note on Wednesday, November 20th. Jefferies Financial Group assumed coverage on QuidelOrtho in a research note on Tuesday, December 10th. They issued a “hold” rating and a $43.00 price target for the company. StockNews.com upgraded QuidelOrtho from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Finally, Citigroup upgraded QuidelOrtho from a “neutral” rating to a “buy” rating and upped their target price for the stock from $44.00 to $50.00 in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, QuidelOrtho currently has a consensus rating of “Hold” and an average target price of $53.43.

Insider Transactions at QuidelOrtho

In related news, CEO Brian J. Blaser acquired 6,033 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was acquired at an average cost of $41.42 per share, for a total transaction of $249,886.86. Following the completion of the acquisition, the chief executive officer now directly owns 6,033 shares of the company’s stock, valued at approximately $249,886.86. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Carlyle Group Inc. sold 8,260,183 shares of the stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $35.31, for a total value of $291,667,061.73. The disclosure for this sale can be found here. Company insiders own 1.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.